India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.
Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...
Hosted on MSN29d
Zydus Lifesciences joins hands with CVS Caremark for diabetes drugs template formularyTemplate formulary is a continually updated list of medications ... to improve glycemic control in adults with type 2 diabetes mellitus. Zydus Pharmaceuticals USA Inc President & CEO Punit ...
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Zydus is committed to unlocking new frontiers in neuroscience and developing transformative breakthrough medicines.” Also known as ZYIL1, Usnoflast has been explored in various pre-clinical ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...
Template formulary is a continually updated list of medications ... to improve glycemic control in adults with type 2 diabetes mellitus. Zydus Pharmaceuticals USA Inc President & CEO Punit ...
Template formulary is a continually updated list of medications, products ... adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Zydus Pharmaceuticals ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback